TA-650 (Infliximab) ( DrugBank: Infliximab )

3 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	1
97	Ulcerative colitis	1
271	Ankylosing spondylitis	1

46. Malignant rheumatoid arthritis

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JapicCTI-050146		12/10/2005	Clinical Study to assess the efficacy and safety of increased dose of TA-650 in patients with Rheumatoid Arthritis	Clinical Study to assess the efficacy and safety of increased dose of TA-650 in patients with Rheumatoid Arthritis	Rheumatoid Arthritis	Intervention name : TA-650 (Infliximab) Dosage And administration of the intervention : Intravenous drip infusion	Mitsubishi Tanabe Pharma Corporation	NULL		20	75	BOTH		Phase 3	NULL

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JapicCTI-060298		24/08/2006	Clinical study to assess the efficacy and safety of TA-650 in patients with active ulcerative colitis	Clinical study to assess the efficacy and safety of TA-650 in patients with active ulcerative colitis	Ulcerative colitis	Intervention name : TA-650 (Infliximab) Dosage And administration of the intervention : Intravenous drip infusion	Mitsubishi Tanabe Pharma Corporation	NULL		16		BOTH		Phase 3	NULL

Clinical trials : 574 / Drugs : 359 - (DrugBank : 68) / Drug target genes : 41 - Drug target pathways : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JapicCTI-070346		22/01/2007	Clinical study of TA-650 in patients with ankylosing spondylitis	Clinical study of TA-650 in patients with ankylosing spondylitis	Ankylosing spondylitis	Intervention name : TA-650 (Infliximab) Dosage And administration of the intervention : Intravenous drip infusion	Mitsubishi Tanabe Pharma Corporation	NULL		16		BOTH		Phase 3	NULL